STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal

We’re finally going to see the actual data for Merck and Moderna’s cancer vaccine. Here’s what to expect Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox. It’s my first time in Madrid. What should I see, other than the inside of the convention center? STAT’s Europe correspondent and I will provide updates from the ESMO Congress there in the ESMO in 30 newsletter. Sign up here. Stuart Franklin/Getty Images The Moderna-Merck cancer vaccine data reveal is days away. Here’s what to expect I left Boston last night and landed in Madrid this morning to report from the European Society for Medical Oncology Congress. I’ll be joined by my colleague Andrew Joseph, who arrived here on a shorter flight from London. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.